View Item 

Show simple item record

Use of Prednisone With Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer
dc.contributor.authorAuchus, Richard J.
dc.contributor.authorYu, Margaret K.
dc.contributor.authorNguyen, Suzanne
dc.contributor.authorMundle, Suneel D.
dc.date.accessioned2017-12-15T16:49:00Z
dc.date.available2017-12-15T16:49:00Z
dc.date.issued2014-12
dc.identifier.citationAuchus, Richard J.; Yu, Margaret K.; Nguyen, Suzanne; Mundle, Suneel D. (2014). "Use of Prednisone With Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer." The Oncologist 19(12): 1231-1240.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/140033
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.subject.other17‐(3‐Pyridyl)‐5,16‐androstadien‐3β‐acetate
dc.subject.otherPrednisone
dc.subject.otherProstatic neoplasms
dc.subject.otherAdrenal cortex hormones
dc.subject.otherSteroid 17‐α‐hydroxylase
dc.titleUse of Prednisone With Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA;
dc.contributor.affiliationotherJanssen Research & Development, Los Angeles, California, USA;
dc.contributor.affiliationotherJanssen Scientific Affairs LLC, Johnson & Johnson, Horsham, Pennsylvania, USA;
dc.contributor.affiliationotherDepartment of Biochemistry, Rush University Medical Center, Chicago, Illinois, USA
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/140033/1/onco1231.pdf
dc.identifier.doi10.1634/theoncologist.2014-0167
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceSR Crowe, JT Merrill, ES Vista. Influenza vaccination responses in human systemic lupus erythematosus: Impact of clinical and demographic features. Arthritis Rheum. 2011; 63: 2396 – 2406.
dc.identifier.citedreferenceJ Owczarek, M Jasińska, D Orszulak‐Michalak. Drug‐induced myopathies. An overview of the possible mechanisms. Pharmacol Rep. 2005; 57: 23 – 34.
dc.identifier.citedreferenceJR Hollister. The untoward effects of steroid treatment on the musculoskeletal system and what to do about them. J Asthma. 1992; 29: 363 – 368.
dc.identifier.citedreferenceHY Lim, N Müller, MJ Herold. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology. 2007; 122: 47 – 53.
dc.identifier.citedreferenceCM Marzocchi‐Machado, EM Russo, CM Alves. Effect of low‐dose prednisone in vivo on the ability of complement receptor to mediate an oxidative burst in rat neutrophils. Immunopharmacology. 2000; 49: 247 – 254.
dc.identifier.citedreferenceF Kanakoudi‐Tsakalidou, M Trachana, P Pratsidou‐Gertsi. Influenza vaccination in children with chronic rheumatic diseases and long‐term immunosuppressive therapy. Clin Exp Rheumatol. 2001; 19: 589 – 594.
dc.identifier.citedreferenceCL Park, AL Frank, M Sullivan. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics. 1996; 98: 196 – 200.
dc.identifier.citedreferenceA Chalmers, D Scheifele, C Patterson. Immunization of patients with rheumatoid arthritis against influenza: A study of vaccine safety and immunogenicity. J Rheumatol. 1994; 21: 1203 – 1206.
dc.identifier.citedreferenceM Naito, K Itoh, N Komatsu. Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. Prostate. 2008; 68: 1753 – 1762.
dc.identifier.citedreferenceEJ Small, RS Lance, CH Redfern. A randomized phase II trial of sipuleucel‐T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate‐resistant prostate cancer (mCRPC). J Clin Oncol. 2013; 31 suppl: 5047a.
dc.identifier.citedreferenceG Attard, AH Reid, R A’Hern. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration‐resistant prostate cancer. J Clin Oncol. 2009; 27: 3742 – 3748.
dc.identifier.citedreferenceCL Loprinzi, JW Kugler, JA Sloan. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999; 17: 3299 – 3306.
dc.identifier.citedreferenceE Zapanti, K Terzidis, G Chrousos. Dysfunction of the hypothalamic‐pituitary‐adrenal axis in HIV infection and disease. Hormones (Athens). 2008; 7: 205 – 216.
dc.identifier.citedreferenceJA Storlie, JC Buckner, GA Wiseman. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma. Cancer. 1995; 76: 96 – 100.
dc.identifier.citedreferenceIF Tannock, D Osoba, MR Stockler. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone‐resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol. 1996; 14: 1756 – 1764.
dc.identifier.citedreferenceR Venkitaraman, K Thomas, RA Huddart. Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer. BJU Int. 2008; 101: 440 – 443.
dc.identifier.citedreferenceVK Arora, E Schenkein, R Murali. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013; 155: 1309 – 1322.
dc.identifier.citedreferenceK Steketee, L Timmerman, AC Ziel‐van der Made. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer. 2002; 100: 309 – 317.
dc.identifier.citedreferenceS Diederich, E Eigendorff, P Burkhardt. 11Beta‐hydroxysteroid dehydrogenase types 1 and 2: An important pharmacokinetic determinant for the activity of synthetic mineralo‐ and glucocorticoids. J Clin Endocrinol Metab. 2002; 87: 5695 – 5701.
dc.identifier.citedreferenceR Hardy, EH Rabbitt, A Filer. Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis. 2008; 67: 1204 – 1210.
dc.identifier.citedreferenceAJ Lawson, EA Walker, GG Lavery. Cortisone‐reductase deficiency associated with heterozygous mutations in 11beta‐hydroxysteroid dehydrogenase type 1. Proc Natl Acad Sci USA. 2011; 108: 4111 – 4116.
dc.identifier.citedreferenceA Brunello, R Kapoor, M Extermann. Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. Am J Clin Oncol. 2011; 34: 292 – 296.
dc.identifier.citedreferenceSE Inzucchi, RM Bergenstal, JB Buse. Management of hyperglycemia in type 2 diabetes: A patient‐centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364 – 1379.
dc.identifier.citedreferenceJP Droz, L Balducci, M Bolla. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol. 2010; 73: 68 – 91.
dc.identifier.citedreferenceSecond‐line treatment of metastatic prostate cancer. Prednisone and radiotherapy for symptom relief. Prescrire Int. 2013; 22: 74 – 78.
dc.identifier.citedreferenceDY Heng, KN Chi. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer. Can J Urol. 2006; 13: 3335 – 3339.
dc.identifier.citedreferenceH Bonkhoff, R Berges. From pathogenesis to prevention of castration resistant prostate cancer. Prostate. 2010; 70: 100 – 112.
dc.identifier.citedreferenceEM Van Allen, CJ Ryan. Novel secondary hormonal therapy in advanced prostate cancer: An update. Curr Opin Urol. 2009; 19: 315 – 321.
dc.identifier.citedreferenceA O’Donnell, I Judson, M Dowsett. Hormonal impact of the 17alpha‐hydroxylase/C(17,20)‐lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004; 90: 2317 – 2325.
dc.identifier.citedreferenceJS De Bono, CJ Logothetis, A Molina. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995 – 2005.
dc.identifier.citedreferenceCJ Ryan, MR Smith, JS De Bono. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368: 138 – 148.
dc.identifier.citedreferenceDC Danila, MJ Morris, JS De Bono. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel‐treated castration‐resistant prostate cancer. J Clin Oncol. 2010; 28: 1496 – 1501.
dc.identifier.citedreferenceAH Reid, G Attard, DC Danila. Significant and sustained antitumor activity in post‐docetaxel, castration‐resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010; 28: 1489 – 1495.
dc.identifier.citedreferenceCJ Ryan, MR Smith, L Fong. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration‐resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010; 28: 1481 – 1488.
dc.identifier.citedreferenceHI Scher, K Fizazi, F Saad. Association of baseline corticosteroid with outcomes in a multivariate analysis of the phase 3 AFFIRM study of enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI). Ann Oncol. 2012; 23 suppl 9: 899PDa.
dc.identifier.citedreferenceMontgomery RB, Kheoh TS, Molina A et al. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration‐resistant prostate cancer: Exploratory analysis from COU‐AA‐301. Eur Urol 2014 [E‐pub ahead of print]
dc.identifier.citedreferenceEA Mostaghel, PS Nelson. Intracrine androgen metabolism in prostate cancer progression: Mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab. 2008; 22: 243 – 258.
dc.identifier.citedreferenceG Attard, AH Reid, TA Yap. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration‐resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008; 26: 4563 – 4571.
dc.identifier.citedreferenceG Attard, AH Reid, RJ Auchus. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab. 2012; 97: 507 – 516.
dc.identifier.citedreferenceM Debono, RJ Ross, J Newell‐Price. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol. 2009; 160: 719 – 729.
dc.identifier.citedreferenceK Fizazi, HI Scher, A Molina. Abiraterone acetate for treatment of metastatic castration‐resistant prostate cancer: Final overall survival analysis of the COU‐AA‐301 randomised, double‐blind, placebo‐controlled phase 3 study. Lancet Oncol. 2012; 13: 983 – 992.
dc.identifier.citedreferenceJ Richards, AC Lim, CW Hay. Interactions of abiraterone, eplerenone, and prednisolone with wild‐type and mutant androgen receptor: A rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012; 72: 2176 – 2182.
dc.identifier.citedreferenceSK Mishra, N Gupta, R Goswami. Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 microg ACTH stimulation in patients with hyperthyroidism before and after carbimazole therapy: Case‐control comparative study. J Clin Endocrinol Metab. 2007; 92: 1693 – 1696.
dc.identifier.citedreferenceLE Ward, HF Polley, MH Power. Prednisone in rheumatoid arthritis: Metabolic and clinical effects. Ann Rheum Dis. 1958; 17: 145 – 159.
dc.identifier.citedreferenceC Grossmann, T Scholz, M Rochel. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV‐1 cells: A comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004; 151: 397 – 406.
dc.identifier.citedreferenceM Costa‐Santos, CE Kater, RJ Auchus. Two prevalent CYP17 mutations and genotype‐phenotype correlations in 24 Brazilian patients with 17‐hydroxylase deficiency. J Clin Endocrinol Metab. 2004; 89: 49 – 60.
dc.identifier.citedreferenceF Costenaro, TC Rodrigues, CE Kater. Combined 17α‐hydroxylase/17,20‐lyase deficiency due to p.R96W mutation in the CYP17 gene in a Brazilian patient. Arq Bras Endocrinol Metabol. 2010; 54: 744 – 748.
dc.identifier.citedreferenceDB Coursin, KE Wood. Corticosteroid supplementation for adrenal insufficiency. JAMA. 2002; 287: 236 – 240.
dc.identifier.citedreferenceTB Dorff, ED Crawford. Management and challenges of corticosteroid therapy in men with metastatic castrate‐resistant prostate cancer. Ann Oncol. 2013; 24: 31 – 38.
dc.identifier.citedreferenceR Dahl. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med. 2006; 100: 1307 – 1317.
dc.identifier.citedreferenceJ Katz. The practical use of corticosteroids in the treatment of inflammatory bowel disease. Pract Gastroenterol. 2005; 29: 14 – 25.
dc.identifier.citedreferenceTP Van Staa, P Geusens, JW Bijlsma. Clinical assessment of the long‐term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54: 3104 – 3112.
dc.identifier.citedreferenceKA Coulson, G Reed, BE Gilliam. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009; 15: 155 – 160.
dc.identifier.citedreferenceSS Yeap, DJ Hosking. Management of corticosteroid‐induced osteoporosis. Rheumatology (Oxford). 2002; 41: 1088 – 1094.
dc.identifier.citedreferenceHW Kelly, ML Van Natta, RA Covar. Effect of long‐term corticosteroid use on bone mineral density in children: A prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics. 2008; 122: e53 – e61.
dc.identifier.citedreferenceH Matsumoto, K Ishihara, T Hasegawa. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients: A 4‐year longitudinal study. Chest. 2001; 120: 1468 – 1473.
dc.identifier.citedreferencePW Speiser, PC White. Congenital adrenal hyperplasia. N Engl J Med. 2003; 349: 776 – 788.
dc.identifier.citedreferenceH Falhammar, H Filipsson Nyström, A Wedell. Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia. Eur J Endocrinol. 2013; 168: 331 – 341.
dc.identifier.citedreferencePW Speiser, R Azziz, LS Baskin. Congenital adrenal hyperplasia due to steroid 21‐hydroxylase deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95: 4133 – 4160.
dc.identifier.citedreferenceC Raúl Ariza‐Andraca, LA Barile‐Fabris, AC Frati‐Munari. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res. 1998; 29: 259 – 262.
dc.identifier.citedreferenceLG Gallon, J Winoto, JR Leventhal. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long‐term renal transplant function. Clin J Am Soc Nephrol. 2006; 1: 1029 – 1038.
dc.identifier.citedreferenceES Brown. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann N Y Acad Sci. 2009; 1179: 41 – 55.
dc.identifier.citedreferenceBG Bender, JA Lerner, E Kollasch. Mood and memory changes in asthmatic children receiving corticosteroids. J Am Acad Child Adolesc Psychiatry. 1988; 27: 720 – 725.
dc.identifier.citedreferenceSH Bolanos, DA Khan, M Hanczyc. Assessment of mood states in patients receiving long‐term corticosteroid therapy and in controls with patient‐rated and clinician‐rated scales. Ann Allergy Asthma Immunol. 2004; 92: 500 – 505.
dc.identifier.citedreferenceW Berry, S Dakhil, M Modiano. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002; 168: 2439 – 2443.
dc.identifier.citedreferenceIF Tannock, R De Wit, WR Berry. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502 – 1512.
dc.identifier.citedreferenceS Romero, G Stanton, J DeFelice. Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy. Urol Oncol. 2007; 25: 284 – 290.
dc.identifier.citedreferenceRathkopf DE, Smith MR, De Bono JS et al. Updated interim efficacy analysis and long‐term safety of abiraterone acetate in metastatic castration‐resistant prostate cancer patients without prior chemotherapy (COU‐AA‐302) Eur Urol 2014 [E‐pub ahead of print]
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco1231.pdf
Size:
1.342MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.